New multiplex assay kits are available that can provide greater insight into the biochemical changes associated with Alzheimer disease, Parkinson disease, and other neurological disorders. The three new Milliplex® MAP kits are validated, multiplexed immunoassays for measuring 21 biomarkers including amyloid beta 1-40 and 1-42, serum amyloid P (SAP), total and phospho-Tau (Thr231), PARK7, and alpha synuclein. Levels of these biomarkers may be predictive of the formation of aggregates that interfere with nervous system functions, resulting in cognitive decline, motor dysfunction, and other symptoms. Based on Luminex technology, the kits enable simultaneous quantification of multiple biomarkers in cerebrospinal fluid, serum, or plasma.